Articles by Charlotte Robinson
A new innovation center in Boston will serve as Roche's cardiovascular, renal, and metabolism research and development hub.
Furosemide (Furoscix) has been approved by the FDA for the treatment of edema in patients with chronic kidney disease (CKD).
Do changes in UPCR during severe AKI episodes affect how serum creatinine levels change at the time of sample collection?
KDIGO has published its first guideline on the evaluation, management, and treatment of ADPKD.
Healthcare professionals who have made significant contributions to the field of kidney disease will be honored at SCM25.
In a Kidney Action Week session, Drs. Camille Campbell and Joshua Denny discussed ways to diversify clinical trials.
Research examined kidney endpoints between patients with type 2 diabetes after initiating an SGLT2i or GLP-1RA.
Canagliflozin increased total iron binding capacity and decreased ferritin in patients with type 2 diabetes and CKD.
In a Kidney Action Week session, Drs. Swapnil Hiremath and Jordana Cohen discussing management of resistant high BP with CKD.
A study evaluated the effectiveness of spironolactone for reducing adverse cardiovascular outcomes in older adults with CKD.
Researchers studied the efficacy of exercise in improving cognitive function in people with CKD and its potential harm.
The American Society of Nephrology published guidance for outpatient management of patients with dialysis-requiring AKI.
World Congress of Nephrology 2025, rare kidney disease, renal nutrition, GLP-1 receptor agonists, and more.
LaVarne Burton of the American Kidney Fund opened Kidney Action Week 2025 with welcome remarks on March 3.
A study compared CV risks and fracture prevention benefits of denosumab versus oral bisphosphonates in patients on dialysis.
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
A study examined MPS-based gene panel testing in patients with unexplained CKD in a real-world context.
Can lower home systolic BP targets be met in patients with CKD through antihypertensive medications and home BP monitoring?
Research examined the role of serum phosphate in CKD-associated pruritus and the efficacy of treatment with difelikefalin.
Eledon Pharmaceuticals CEO David-Alexandre Gros, MD, spoke about the role of CD40L blocker tegoprubart in transplantation.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.